Please login to the form below

Not currently logged in

Lucid Group promotes Clare Reynolds to newly created role

Reynolds initially joined Lucid in 2009 as business unit director

Lucid Group has promoted Clare Reynolds (pictured above) to director of business development and commercial integration.

Reynolds initially joined Lucid in 2009 as business unit director – since then, she has progressed through the ranks at the medcomms company, most recently working as senior managing partner.

In a statement, Lucid said Reynolds had played a 'key role' in developing new and existing clients for the company, leading to the promotion.

In her new role, Reynolds will aim to enhance Lucid's ability to improve health outcomes and also build on the company's strategic partnerships.

She will also lead the introduction of new capabilities into Lucid's teams to attract new clients, companies and candidates.

"By firmly engaging with this intent through our client partnerships, we lead with improving patient outcomes and build our business in the process," commented Reynolds.

"This new role creates the opportunity to more tangibly align the way we approach our client partnerships with our vision, and to expand our capabilities in a way that brings incremental value to our clients and the healthcare communities within which we work," she added.

Prior to Lucid, Reynolds served as marketing director, HIV International for Gilead Sciences.

Article by
Lucy Parsons

29th April 2021

From: Marketing


COVID-19 Updates and Daily News

Featured jobs


Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....